UTI Mid Cap Fund
The scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of mid cap companies.
Growthvine rating: 2/5 — ranked #26 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹297.29 (as of 2026-10-01) |
|---|
| AUM | ₹12,795 Cr |
|---|
| Expense ratio | 1.47% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Vishal Chopda |
|---|
| Exit load | 1% for redemption within 364 days |
|---|
Performance & risk
| 5-year annualised return | 9.93% |
|---|
| Sharpe ratio | 0.45 |
|---|
| Standard deviation | 17.34% |
|---|
| Max drawdown | −68.39% |
|---|
| Alpha | -4.21 |
|---|
| Beta | 0.95 |
|---|
Over 5 years, captured 85.7% of NIFTY Midcap 150's upside and 99.0% of its downside.
Market cap allocation
| Large cap | 12.8% |
|---|
| Mid cap | 68.0% |
|---|
| Small cap | 19.2% |
|---|
Concentration
| Top 5 holdings | 13.7% |
|---|
| Top 10 holdings | 24.1% |
|---|
| Total holdings | 81 |
|---|
| Index overlap | 42.0% |
|---|
| Active share | 58.0% |
|---|
Top holdings
- COFORGE LIMITED — 3.3%
- PB Fintech Limited — 3.1%
- AU Small Finance Bank Limited — 2.8%
- APL Apollo Tubes Limited — 2.4%
- Hero MotoCorp Limited — 2.2%
- Aurobindo Pharma Ltd. — 2.2%
- Federal Bank Ltd. — 2.1%
- Ajanta Pharma Ltd. — 2.1%
- Polycab India Limited — 2.1%
- Shriram Finance Limited — 2.0%
Top sectors
- Banking & Financial — 13.8%
- Pharma & Biotech — 9.7%
- Retail — 9.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −2.1% | Q4 (Bottom) | #26 of 31 |
| 2025 | −0.1% | Q4 (Bottom) | #23 of 29 |
| 2024 | 23.3% | Q3 | #21 of 29 |
| 2023 | 30.5% | Q4 (Bottom) | #26 of 28 |
| 2022 | −0.8% | Q3 | #17 of 22 |